Arvinas (NASDAQ:ARVN - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44, Zacks reports. During the same quarter in the previous year, the company earned ($2.53) earnings per share.
Arvinas Price Performance
Shares of ARVN stock traded up $0.51 during trading hours on Friday, reaching $18.18. The stock had a trading volume of 607,081 shares, compared to its average volume of 901,601. Arvinas has a twelve month low of $16.61 and a twelve month high of $53.08. The firm has a 50-day simple moving average of $19.04 and a 200-day simple moving average of $23.28. The firm has a market capitalization of $1.25 billion, a PE ratio of -3.86 and a beta of 1.88.
Wall Street Analysts Forecast Growth
ARVN has been the subject of several analyst reports. Wedbush restated an "outperform" rating and issued a $57.00 target price on shares of Arvinas in a research note on Tuesday. BTIG Research began coverage on shares of Arvinas in a research note on Tuesday, December 10th. They set a "buy" rating and a $69.00 price objective on the stock. Guggenheim reiterated a "buy" rating and set a $57.00 price objective on shares of Arvinas in a research note on Wednesday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th. Finally, Oppenheimer increased their price objective on shares of Arvinas from $40.00 to $45.00 and gave the company an "outperform" rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $59.58.
Read Our Latest Analysis on ARVN
Arvinas Company Profile
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Featured Stories
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
